<DOC>
	<DOCNO>NCT01927341</DOCNO>
	<brief_summary>The primary purpose phase Ib estimate MTD/RPD2 phase II assess anti-tumor activity MEK162 combination panitumumab .</brief_summary>
	<brief_title>Phase Ib/II Study Efficacy Safety MEK162 Panitumumab , Adult mCRC Patients With Mutant Wild-type RAS Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age ≥ 18 year Metastatic colorectal cancer Progression follow standard therapy , standard therapy ( phase Ib ) . Progression follow least 2prior fluoropyrimidinecontaining chemotherapy regimen ( phase II ) Written documentation mutant wildtype RAS Life expectancy ≥ 3 month ECOG performance status ≤ 2 Phase II arm 1 4 : previous treatment cetuximab , panitumumab , and/or EGFR inhibitor Previous treatment MEKinhibitors History severe infusion reaction monoclonal antibody . Symptomatic untreated leptomeningeal disease Symptomatic brain metastasis Current evidence retinal disease ; history CSR , RVO ophthalmopathy assess ophthalmologic examination baseline would consider risk factor CSR/RVO history keratitis . Acute chronic pancreatitis Clinically significant cardiac disease Not adequate hematologic , renal hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>MEK162 ,</keyword>
	<keyword>panitumumab ,</keyword>
	<keyword>mutant RAS ,</keyword>
	<keyword>wild-type RAS ,</keyword>
	<keyword>metastatic colorectal cancer ,</keyword>
	<keyword>adult mCRC patient</keyword>
</DOC>